Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Perrigo
PRGO
|
+$672M |
| 2 |
Merck
MRK
|
+$608M |
| 3 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$384M |
| 4 |
Las Vegas Sands
LVS
|
+$378M |
| 5 |
TFCFA
Twenty-First Century Fox, Inc. Class A
TFCFA
|
+$303M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ralph Lauren
RL
|
+$518M |
| 2 |
eBay
EBAY
|
+$474M |
| 3 |
Estee Lauder
EL
|
+$435M |
| 4 |
Goldman Sachs
GS
|
+$323M |
| 5 |
TechnipFMC
FTI
|
+$304M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.03% |
| 2 | Consumer Discretionary | 13.85% |
| 3 | Communication Services | 11.23% |
| 4 | Technology | 10.46% |
| 5 | Energy | 9.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PLG
501
Platinum Group Metals
PLG
$160M
| $7.37M | 0.01% |
73,661
-1,088
| -1% | -$125K |
|
|
HSTO
502
DELISTED
Histogen Inc. Common Stock
HSTO
| $6.91M | 0.01% |
4,249
+11
| +0.3% | +$23K |
|
|
CSLT
503
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
| $6.9M | 0.01% |
+325,000
| New | +$9.42M |
|
|
YOKU
504
DELISTED
YOUKU TUDOU INC.(CAYMAN ISLS)
YOKU
| $6.84M | 0.01% |
243,950
+3,153
| +1% | +$98K |
|
|
TVRD
505
Tvardi Therapeutics
TVRD
$20.1M
| $6.59M | 0.01% |
+9,844
| New | +$5.82M |
|
506
Tempest Therapeutics
TPST
$14.3M
| $6.36M | 0.01% |
+243
| New | +$6.89M |
|
|
QUOT
507
DELISTED
Quotient Technology Inc
QUOT
| $6.12M | 0.01% |
+248,152
| New | +$6.72M |
|
508
ExxonMobil
XOM
$650B
| $5.96M | 0.01% |
61,071
+218
| +0.4% | +$20.8K |
|
|
STAY
509
DELISTED
Extended Stay America, Inc. Paired Share Unit
STAY
| $5.66M | 0.01% |
248,551
+55,164
| +29% | +$1.38M |
|
|
RVNC
510
DELISTED
Revance Therapeutics, Inc.
RVNC
| $5.51M | 0.01% |
+174,972
| New | +$5.47M |
|
|
AERI
511
DELISTED
Aerie Pharmaceuticals
AERI
| $5.46M | 0.01% |
257,712
+848
| +0.3% | +$17.1K |
|
512
Verastem
VSTM
$528M
| $5.43M | 0.01% |
41,970
+140
| +0.3% | +$22.3K |
|
513
InspireMD
NSPR
$31.4M
| – | – |
0
| – | – |
|
514
WSFS Financial
WSFS
$4.14B
| $5.27M | 0.01% |
221,388
-448,419
| -67% | -$10.8M |
|
|
TRNX
515
DELISTED
TORNIER N V SHARES (NLD)
TRNX
| $5.07M | ﹤0.01% |
238,712
+769
| +0.3% | +$14.9K |
|
516
IQVIA
IQV
$40.7B
| $5.04M | ﹤0.01% |
99,360
+215
| +0.2% | +$10.8K |
|
517
Kirby Corp
KEX
$7.01B
| $4.92M | ﹤0.01% |
48,609
-213,272
| -81% | -$21.5M |
|
|
SUNE
518
DELISTED
SUNEDISON, INC COM
SUNE
| $4.71M | ﹤0.01% |
+250,164
| New | +$4.17M |
|
519
State Street SPDR S&P 500 ETF Trust
SPY
$771B
| $4.56M | ﹤0.01% |
24,365
-38,143
| -61% | -$7M |
|
520
Webster Financial
WBS
$12.3B
| $4.54M | ﹤0.01% |
146,027
+30,186
| +26% | +$927K |
|
|
FL
521
DELISTED
Foot Locker
FL
| $4.37M | ﹤0.01% |
92,964
+47,987
| +107% | +$1.99M |
|
522
Insulet
PODD
$11.8B
| $4.28M | ﹤0.01% |
90,174
-458,506
| -84% | -$20.3M |
|
523
Omeros
OMER
$845M
| $4.22M | ﹤0.01% |
+350,000
| New | +$4.3M |
|
524
Inovio Pharmaceuticals
INO
$85.6M
| $4.16M | ﹤0.01% |
+26,042
| New | +$3.74M |
|
|
AENZ
525
DELISTED
Aenza S.A.A.
AENZ
| $4.13M | ﹤0.01% |
79,697
+2,873
| +4% | +$170K |
|
Similar funds
Jennison Associates's Q1 2014 Portfolio in Review
As of Q1 2014, Jennison Associates held 826 positions worth $105B, up 2.6% from $102B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Jennison Associates's Q1 2014 filing shows 122 new, 275 increased, 321 reduced and 94 closed positions. Its largest new stake was Perrigo: 4,257,843 shares worth $659M. The largest sale was Ralph Lauren, an estimated $518M.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, up from 18% a quarter earlier, followed by Consumer Discretionary and Communication Services.
- Jennison Associates's largest Q1 2014 buy was Perrigo: 4,257,843 shares worth $659M.
- Jennison Associates added most to Merck in Q1 2014, an estimated $608M increase.
- Jennison Associates's biggest Q1 2014 reduction was Estee Lauder, cutting an estimated $435M.
- Jennison Associates fully exited Ralph Lauren in Q1 2014, selling an estimated $518M.
- Jennison Associates's ten largest holdings make up 18% of its $105B portfolio in Q1 2014.
- Jennison Associates opened 122 new positions and closed 94 in Q1 2014.
- Jennison Associates's portfolio value rose 2.6% quarter-over-quarter to $105B.
Based on Jennison Associates's 13F filing for Q1 2014, filed 7 May 2014.